PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy

Ruedesheim Sabine M.

首页> 外文期刊>Oncology research and treatment. >PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy

【24h】

PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy

机译：PARP抑制剂晚期BRCA1 / 2乳腺癌Talazoparib：延长无需化疗的无进展生存

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2020年第8期|共1页
作者
Ruedesheim Sabine M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy [J] . Ruedesheim Sabine M. Oncology research and treatment. . 2020,第7a8期

机译：PARP抑制剂晚期BRCA1 / 2乳腺癌Talazoparib：延长无需化疗的无进展生存
2. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib [J] . McCann Kelly E. Future oncology . 2019,第15期

机译：用于BRCA1 / 2相关乳腺癌的PARP抑制剂的使用进展：TALAZOPARIB
3. PARP Inhibition in advanced gBRCA1/2 mutated Breast Cancer New AGO Guideline on Breast cancer published: PARP Inhibitors have highest possible Level of Recommendation [J] . Breast care . 2021,第3期

机译：PARP抑制在先进的GBRCA1 / 2突变乳腺癌新前乳腺癌的指导发表：PARP抑制剂具有最高水平的建议
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The Influence of Stress Hormones on Breast Cancer Stem Cell Survival and Chemotherapy Resistance [D] . Courtney, Angela 2015

机译：应激激素对乳腺癌干细胞存活和化疗耐药性的影响
6. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [O] . Ting Ding, Fei Zhou, Xiaoxia Chen, 2017

机译：吉非替尼加化学疗法的继续治疗可延长晚期非小细胞肺癌患者的无进展生存期这些患者对吉非替尼具有无T790M突变的获得性耐药
7. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [O] . Ting Ding, Fei Zhou, Xiaoxia Chen, 2017

机译：Gefitinib Plus化疗的延续延长了高级非小细胞肺癌患者的无进展生存率，他们因没有T790M突变而获得吉维替尼的抗性
8. Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy [R] . DeSoto, J. A. 2008

机译：聚（aDp-核糖）paRp-1抑制剂和化疗治疗BRCa1 / 2遗传性乳腺癌和散发性乳腺癌

PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy

著录项

相似文献

相关主题

期刊订阅